Q-omics provides the consensus-scored EIF2S2P7 profile across patient tissues and cancer cell-line models. EIF2S2P7 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, EIF2S2P7 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, EIF2S2P7 RNA expression shows 5,621 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, and STAD as cancer lineages where EIF2S2P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF2S2P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF2S2P7 survival associations across molecular data types. EIF2S2P7 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF2S2P7 RNA expression–survival associations across cancer types. High EIF2S2P7 expression shows unfavorable associations in ESCA, CESC, STAD, KIRC, GBM and READ. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for EIF2S2P7 RNA expression.
This table summarizes EIF2S2P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF2S2P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF2S2P7 shows lower tumor expression in STAD. The STAD box plot shows higher EIF2S2P7 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .038).
This table shows molecular features associated with EIF2S2P7 in patient tissues and cancer cell lines. In patient samples, EIF2S2P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
